Synsam AB (publ) (SYNSAM.ST)
SEK 42.3
(0.83%)
SEK 42.3
(0.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 311 Million SEK | -5.18% |
| 2022 | 328 Million SEK | 543.14% |
| 2021 | 51 Million SEK | 126.13% |
| 2020 | -195.2 Million SEK | -9.66% |
| 2019 | -178 Million SEK | 40.59% |
| 2018 | -299.6 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 56 Million SEK | -9.68% |
| 2024 Q2 | 168 Million SEK | 200.0% |
| 2023 Q2 | 140 Million SEK | 636.84% |
| 2023 FY | 311 Million SEK | -5.18% |
| 2023 Q4 | 62 Million SEK | -31.11% |
| 2023 Q3 | 90 Million SEK | -35.71% |
| 2023 Q1 | 19 Million SEK | -62.75% |
| 2022 Q1 | 99 Million SEK | 106.25% |
| 2022 Q4 | 51 Million SEK | -36.25% |
| 2022 Q3 | 80 Million SEK | -17.53% |
| 2022 Q2 | 97 Million SEK | -2.02% |
| 2022 FY | 328 Million SEK | 543.14% |
| 2021 Q1 | -12 Million SEK | 64.71% |
| 2021 FY | 51 Million SEK | 126.13% |
| 2021 Q2 | 14 Million SEK | 216.67% |
| 2021 Q4 | 48 Million SEK | 2300.0% |
| 2021 Q3 | 2 Million SEK | -85.71% |
| 2020 FY | -195.2 Million SEK | -9.66% |
| 2020 Q3 | -25 Million SEK | 69.14% |
| 2020 Q1 | -68.5 Million SEK | 0.0% |
| 2020 Q4 | -34 Million SEK | -36.0% |
| 2020 Q2 | -81 Million SEK | -18.25% |
| 2019 FY | -178 Million SEK | 40.59% |
| 2018 FY | -299.6 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AddLife AB (publ) | 190 Million SEK | -63.684% |
| Biotage AB (publ) | 246 Million SEK | -26.423% |
| Bonesupport Holding AB (publ) | 245.02 Million SEK | -26.928% |
| Doxa AB (publ) | 291.9 Million SEK | -6.543% |
| Elekta AB (publ) | 1.3 Billion SEK | 76.114% |
| iZafe Group AB (publ) | -32.17 Million SEK | 1066.589% |
| Ortivus AB (publ) | -18.24 Million SEK | 1804.577% |
| Ortivus AB (publ) | -18.24 Million SEK | 1804.577% |
| Q-linea AB (publ) | -229.36 Million SEK | 235.591% |
| S2Medical AB (publ) | -22.7 Million SEK | 1469.594% |